Clinical Highlights

Aesthetics

Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program

Dermatologic Surgery

Author: Cohen, Joel L. et al.
Published on February 8, 2021

Aesthetics

Advanced Concepts in Rheology for the Evaluation of Hyaluronic Acid–Based Soft Tissue Fillers

Dermatologic Surgery

Author: Faivre, Jimmy et al.
Published on January 21, 2021

Aesthetics

A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines

Dermatologic Surgery

Author: Green, Jeremy B. MD et al.
Published on August 6, 2020

Aesthetics

DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study

Dermatologic Surgery

Author: Fabi, Sabrina G. MD et al.
Published on August 6, 2020

Aesthetics

Efficacy and Safety of Two Resilient Hyaluronic Acid Fillers in the Treatment of Moderate-to-Severe Nasolabial Folds

Dermatologic Surgery

Author: Gary Monheit, M.D.
Published on March 24, 2020

Aesthetics

DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)

Journal of the American Academy of Dermatology

Author: Vince Bertucci, M.D. et al
Published on December 2, 2019

Disclaimers

DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA and is currently under regulatory review.
* DaxibotulinumtoxinA for Injection was formerly known as RT002.

Clinical Highlights

Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program

Advanced Concepts in Rheology for the Evaluation of Hyaluronic Acid–Based Soft Tissue Fillers

A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines

DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study

Efficacy and Safety of Two Resilient Hyaluronic Acid Fillers in the Treatment of Moderate-to-Severe Nasolabial Folds

DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2)

Disclaimers

Aesthetics

Therapeutics

Investors

Company

News

Careers